Scribe Therapeutics Positions Epigenetic CRISPR for Durable LDL-C Reduction
CRISPR Medicine News
|
March 25, 2026
X min read
CRISPR Medicine News
|
March 25, 2026
Share on Social
More like this
Media
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
Press
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
